Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enobosarm + anastrozole
- Development stage
- Phase 1
- Lead developer
- Veru
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**enobosarm + anastrozole** is a combination of two small-molecule pharmaceuticals: enobosarm, a selective androgen receptor modulator (SARM), and anastrozole, a nonsteroidal aromatase inhibitor. Enobosarm acts as an agonist at the androgen receptor, promoting anabolic activity without significant masculinizing side effects. Anastrozole inhibits the enzyme aromatase, thereby reducing estrogen biosynthesis. The combination is being investigated for its potential to suppress estrogen production while harnessing the antitumor and anabolic effects of targeted androgen receptor activation, particularly in certain breast cancer populations.
02
Targets
AR (Adrenergic receptors)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on enobosarm + anastrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enobosarm + anastrozole.